279 related articles for article (PubMed ID: 23979133)
1. Llama-derived single variable domains (nanobodies) directed against chemokine receptor CXCR7 reduce head and neck cancer cell growth in vivo.
Maussang D; Mujić-Delić A; Descamps FJ; Stortelers C; Vanlandschoot P; Stigter-van Walsum M; Vischer HF; van Roy M; Vosjan M; Gonzalez-Pajuelo M; van Dongen GA; Merchiers P; van Rompaey P; Smit MJ
J Biol Chem; 2013 Oct; 288(41):29562-72. PubMed ID: 23979133
[TBL] [Abstract][Full Text] [Related]
2. Imaging ligand-dependent activation of CXCR7.
Luker KE; Gupta M; Steele JM; Foerster BR; Luker GD
Neoplasia; 2009 Oct; 11(10):1022-35. PubMed ID: 19794961
[TBL] [Abstract][Full Text] [Related]
3. Chemokine CXCL12 activates dual CXCR4 and CXCR7-mediated signaling pathways in pancreatic cancer cells.
Heinrich EL; Lee W; Lu J; Lowy AM; Kim J
J Transl Med; 2012 Apr; 10():68. PubMed ID: 22472349
[TBL] [Abstract][Full Text] [Related]
4. Allosteric peptide regulators of chemokine receptors CXCR4 and CXCR7.
Ehrlich A; Ray P; Luker KE; Lolis EJ; Luker GD
Biochem Pharmacol; 2013 Nov; 86(9):1263-71. PubMed ID: 23973527
[TBL] [Abstract][Full Text] [Related]
5. Constitutive and chemokine-dependent internalization and recycling of CXCR7 in breast cancer cells to degrade chemokine ligands.
Luker KE; Steele JM; Mihalko LA; Ray P; Luker GD
Oncogene; 2010 Aug; 29(32):4599-610. PubMed ID: 20531309
[TBL] [Abstract][Full Text] [Related]
6. The peptidomimetic CXCR4 antagonist TC14012 recruits beta-arrestin to CXCR7: roles of receptor domains.
Gravel S; Malouf C; Boulais PE; Berchiche YA; Oishi S; Fujii N; Leduc R; Sinnett D; Heveker N
J Biol Chem; 2010 Dec; 285(49):37939-43. PubMed ID: 20956518
[TBL] [Abstract][Full Text] [Related]
7. CXCR7 controls competition for recruitment of β-arrestin 2 in cells expressing both CXCR4 and CXCR7.
Coggins NL; Trakimas D; Chang SL; Ehrlich A; Ray P; Luker KE; Linderman JJ; Luker GD
PLoS One; 2014; 9(6):e98328. PubMed ID: 24896823
[TBL] [Abstract][Full Text] [Related]
8. The chemokine receptor CXCR7 interacts with EGFR to promote breast cancer cell proliferation.
Salazar N; Muñoz D; Kallifatidis G; Singh RK; Jordà M; Lokeshwar BL
Mol Cancer; 2014 Aug; 13():198. PubMed ID: 25168820
[TBL] [Abstract][Full Text] [Related]
9. The presumed atypical chemokine receptor CXCR7 signals through G(i/o) proteins in primary rodent astrocytes and human glioma cells.
Odemis V; Lipfert J; Kraft R; Hajek P; Abraham G; Hattermann K; Mentlein R; Engele J
Glia; 2012 Mar; 60(3):372-81. PubMed ID: 22083878
[TBL] [Abstract][Full Text] [Related]
10. G protein‑mediated EGFR transactivation is a common mechanism through which the CXCL12 receptors, CXCR4 and CXCR7, control human cancer cell migration.
Zieger-Naumann K; Kuhl F; Engele J
Oncol Rep; 2024 Feb; 51(2):. PubMed ID: 38099418
[TBL] [Abstract][Full Text] [Related]
11. CXCL12-CXCR4/CXCR7 Axis in Colorectal Cancer: Therapeutic Target in Preclinical and Clinical Studies.
Khare T; Bissonnette M; Khare S
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298991
[TBL] [Abstract][Full Text] [Related]
12. Neutralizing nanobodies targeting diverse chemokines effectively inhibit chemokine function.
Blanchetot C; Verzijl D; Mujić-Delić A; Bosch L; Rem L; Leurs R; Verrips CT; Saunders M; de Haard H; Smit MJ
J Biol Chem; 2013 Aug; 288(35):25173-25182. PubMed ID: 23836909
[TBL] [Abstract][Full Text] [Related]
13. C-X-C motif chemokine 12/C-X-C chemokine receptor type 7 signaling regulates breast cancer growth and metastasis by modulating the tumor microenvironment.
Wani N; Nasser MW; Ahirwar DK; Zhao H; Miao Z; Shilo K; Ganju RK
Breast Cancer Res; 2014 May; 16(3):R54. PubMed ID: 24886617
[TBL] [Abstract][Full Text] [Related]
14. Scavenging of CXCL12 by CXCR7 promotes tumor growth and metastasis of CXCR4-positive breast cancer cells.
Luker KE; Lewin SA; Mihalko LA; Schmidt BT; Winkler JS; Coggins NL; Thomas DG; Luker GD
Oncogene; 2012 Nov; 31(45):4750-8. PubMed ID: 22266857
[TBL] [Abstract][Full Text] [Related]
15. Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR Nanobodies.
Roovers RC; Laeremans T; Huang L; De Taeye S; Verkleij AJ; Revets H; de Haard HJ; van Bergen en Henegouwen PM
Cancer Immunol Immunother; 2007 Mar; 56(3):303-317. PubMed ID: 16738850
[TBL] [Abstract][Full Text] [Related]
16. Silencing of CXCR7 gene represses growth and invasion and induces apoptosis in colorectal cancer through ERK and β-arrestin pathways.
Li XX; Zheng HT; Huang LY; Shi DB; Peng JJ; Liang L; Cai SJ
Int J Oncol; 2014 Oct; 45(4):1649-57. PubMed ID: 25051350
[TBL] [Abstract][Full Text] [Related]
17. CXCR7 participates in CXCL12-induced CD34+ cell cycling through β-arrestin-dependent Akt activation.
Torossian F; Anginot A; Chabanon A; Clay D; Guerton B; Desterke C; Boutin L; Marullo S; Scott MG; Lataillade JJ; Le Bousse-Kerdilès MC
Blood; 2014 Jan; 123(2):191-202. PubMed ID: 24277075
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of CXCR7 inhibits proliferative capacity and stem cell-like properties in breast cancer stem cells.
Tang X; Li X; Li Z; Liu Y; Yao L; Song S; Yang H; Li C
Tumour Biol; 2016 Oct; 37(10):13425-13433. PubMed ID: 27460092
[TBL] [Abstract][Full Text] [Related]
19. CXCR7 as a novel therapeutic target for advanced prostate cancer.
Gritsina G; Yu J
Oncogene; 2023 Mar; 42(11):785-792. PubMed ID: 36755058
[TBL] [Abstract][Full Text] [Related]
20. The CXCL12/CXCR7 signalling axis promotes proliferation and metastasis in cervical cancer.
Xu L; Li C; Hua F; Liu X
Med Oncol; 2021 Apr; 38(5):58. PubMed ID: 33847822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
